Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neurofibromatosis 1 7Neurofibroma, Plexiform 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Recurrence 1Pain 1Neoplasms 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Melanoma 1Gallbladder Neoplasms 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1

Interventions

pembrolizumab 25Cyclophosphamide 20Nivolumab 13Doxorubicin 13Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Exercise 9atezolizumab 8Vincristine 8Rituximab 8Radiotherapy 8Prednisone 8Dexamethasone 8Bevacizumab 8venetoclax 7fludarabine 7Pemetrexed 7Fluorouracil 7Docetaxel 7Blood Specimen Collection 7lenvatinib 6dostarlimab 6cemiplimab 6budigalimab 6Oxaliplatin 6Cisplatin 6durvalumab 5Leucovorin 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms × AZD 6244 × Clear all
NCT00463814 2026-05-29

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

AstraZeneca

Phase 1 Active not recruiting
58 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡